Table 1.
Demographic and baseline characteristics (mITT population).
| Characteristic | Total (n = 305) | LOCF endpoint SR |
|
|---|---|---|---|
| Yes (n = 172) | No (n = 133) | ||
| Age, years | n = 305 | n = 172 | n = 133 |
| Mean (SD) | 36.5 (8.0) | 35.9 (8.0) | 37.2 (8.0) |
| Males, n (%) | 200 (65.6) | 107 (62.2) | 93 (69.9) |
| Weight, kg | n = 303 | n = 171 | n = 132 |
| Mean (SD) | 80.8 (18.1) | 79.8 (16.6) | 82.2 (19.9) |
| BMI, kg/m 2 | n = 303 | n = 171 | n = 132 |
| Mean (SD) | 27.4 (5.2) | 27.2 (4.8) | 27.7 (5.7) |
| Schizophrenia duration from diagnosis, years | n = 304 | n = 171 | n = 133 |
| Mean (SD) | 9.2 (7.3) | 8.6 (6.9) | 10.0 (7.7) |
| Previous hospitalizations for psychiatric reasons, n (%) | n = 304 | n = 171 | n = 133 |
| Yes | 255 (83.9) | 140 (81.9) | 115 (86.5) |
| No | 47 (15.5) | 29 (17.0) | 18 (13.5) |
| Unknown | 2 (0.7) | 2 (1.2) | 0 |
| Total number of previous hospitalizations for psychiatric reasons, n (%) | n = 255 | n = 140 | n = 115 |
| Mean (SD) | 3.3 (3.8) | 3.1 (3.6) | 3.4 (4.0) |
| Last PP1M dose category, n (%) | n = 305 | n = 172 | n = 133 |
| 50 mg | 27 (8.9) | 16 (9.3) | 11 (8.3) |
| 75 mg | 74 (24.3) | 43 (25.0) | 31 (23.3) |
| 100 mg | 114 (37.4) | 63 (36.6) | 51 (38.3) |
| 150 mg | 90 (29.5) | 50 (29.1) | 40 (30.1) |
BMI, body mass index; LOCF, last observation carried forward; mITT, modified intent-to-treat; PP1M, paliperidone palmitate 1-month formulation; SD, standard deviation; SR, symptomatic remission.